|
PRKAA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.28879999997211E-06 |
| Normal-vs-Stage3 |
6.11821704410431E-12 |
| Normal-vs-Stage4 |
1.31006316905768E-14 |
| Stage1-vs-Stage2 |
2.076200E-02 |
| Stage1-vs-Stage3 |
9.915600E-01 |
| Stage1-vs-Stage4 |
8.620000E-02 |
| Stage2-vs-Stage3 |
7.190400E-02 |
| Stage2-vs-Stage4 |
1.761560E-03 |
| Stage3-vs-Stage4 |
1.161030E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.93819999999767E-05 |
| Normal-vs-Asian |
5.09750019972444E-11 |
| Caucasian-vs-AfricanAmerican |
1.207570E-01 |
| Caucasian-vs-Asian |
6.605600E-01 |
| AfricanAmerican-vs-Asian |
9.946000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.04360964314765E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.067400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
3.54161144855425E-14 |
| Normal-vs-Age(61-80Yrs) |
1.83949522281068E-11 |
| Normal-vs-Age(81-100Yrs) |
2.178800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.366200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.697850E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.936200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.306200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.487400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.502400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.903000E-03 |
| Classical-VS-Follicular |
2.802900E-03 |
| Classical-VS-Other |
7.720600E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.2598999999901E-05 |
| Tall-VS-Other |
1.026820E-01 |
| Tall-VS-Normal |
6.43929354282591E-15 |
| Follicular-VS-Other |
5.274600E-01 |
| Follicular-VS-Normal |
3.08069999954697E-07 |
| Other-VS-Normal |
3.084800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.76205749780456E-14 |
| Normal-vs-N1 |
4.66293670342566E-15 |
| N0-vs-N1 |
6.301500E-03 |
|
|
